{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:35:54Z","timestamp":1777631754689,"version":"3.51.4"},"reference-count":23,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 5-year-old boy presents with platelet count of 2 \u00d7 109\/L and clinical and laboratory evidence of immune thrombocytopenia. He has epistaxis and oral mucosal bleeding. Complete blood count reveals isolated thrombocytopenia without any decline in hemoglobin and he is Rh+. You are asked if anti-D immunoglobulin is an appropriate initial therapy for this child given the 2010 Food and Drug Administration \u201cblack-box\u201d warning.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.283","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"283-285","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia?"],"prefix":"10.1182","volume":"2013","author":[{"given":"Jenny M.","family":"Despotovic","sequence":"first","affiliation":[{"name":"Hematology Service, Texas Children's Cancer Center, Houston, TX; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy E.","family":"Neunert","sequence":"additional","affiliation":[{"name":"Cancer Center, Georgia Regents University, Augusta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2020071613410414300_B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020071613410414300_B2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jpeds.2005.11.019","article-title":"Single dose of anti-D immune globulin at 75 microg\/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children","volume":"148","author":"Tarantino","year":"2006","journal-title":"J Pediatr"},{"issue":"5","key":"2020071613410414300_B3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1537-2995.2011.03384.x","article-title":"RhIG for the treatment of immune thrombocytopenia: consensus and controversy","volume":"52","author":"Despotovic","year":"2012","journal-title":"Transfusion"},{"issue":"16","key":"2020071613410414300_B4","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"2020071613410414300_B5","unstructured":"US Food and Drug Administration\n          WinRho SDF (Rho(D) immune globulin intravenous (human): risk of intravascular hemolysis\n          Accessed September 26, 2013\n          Available from: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm203739.htm"},{"issue":"3","key":"2020071613410414300_B6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.22261","article-title":"Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects","volume":"87","author":"Long","year":"2012","journal-title":"Am J Hematol"},{"issue":"11","key":"2020071613410414300_B7","doi-asserted-by":"crossref","first-page":"E149","DOI":"10.1002\/pbc.24633","article-title":"Anti-D immunoglobulin therapy for pediatric ITP: before and after the FDA's black box warning","volume":"60","author":"Thompson","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2020071613410414300_B8","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.V89.8.2689","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients","volume":"89","author":"Scaradavou","year":"1997","journal-title":"Blood"},{"issue":"8","key":"2020071613410414300_B9","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.V95.8.2523","article-title":"Acute onset hemoglobinemia and\/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients","volume":"95","author":"Gaines","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2020071613410414300_B10","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2004-11-4303","article-title":"Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura","volume":"106","author":"Gaines","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2020071613410414300_B11","first-page":"248","article-title":"A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high dose immunoglobulins and anti-D immunoglobulins","volume":"77","author":"Rodeghiero","year":"1992","journal-title":"Haematologica"},{"issue":"8924","key":"2020071613410414300_B12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet"},{"issue":"9","key":"2020071613410414300_B13","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.V77.9.1884.1884","article-title":"Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect","volume":"77","author":"Bussel","year":"1991","journal-title":"Blood"},{"key":"2020071613410414300_B14","first-page":"23","article-title":"Efficacy, safety and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children","volume":"35","author":"Freiberg","year":"1998","journal-title":"Semin Hematol"},{"issue":"4","key":"2020071613410414300_B15","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1046\/j.1365-2141.2001.02627.x","article-title":"A dose of 75 microg\/kg\/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg\/kg\/d in adults with immune thrombocytopenic purpura","volume":"112","author":"Newman","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"2020071613410414300_B16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.10424","article-title":"Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care","volume":"74","author":"George","year":"2003","journal-title":"Am J Hematol"},{"issue":"8","key":"2020071613410414300_B17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MPH.0b013e31817541ba","article-title":"A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children","volume":"30","author":"Son","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"2020071613410414300_B18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s12098-008-0243-y","article-title":"Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura","volume":"75","author":"Shahgholi","year":"2008","journal-title":"Indian J Pediatr"},{"issue":"7","key":"2020071613410414300_B19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/09537100903144617","article-title":"Efficacy and safety of anti-D for the treatment of adults with immune thrombocytopenia","volume":"20","author":"Naithani","year":"2009","journal-title":"Platelets"},{"issue":"1","key":"2020071613410414300_B20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2009.08057.x","article-title":"Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura","volume":"149","author":"Kane","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"2020071613410414300_B21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPH.0b013e31820e2aa5","article-title":"Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia","volume":"33","author":"Papagianni","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2020071613410414300_B22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11239-012-0801-z","article-title":"Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura","volume":"35","author":"Celik","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2020071613410414300_B23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MBC.0b013e32835e5337","article-title":"A comparison of intravenous immunoglobulin (2g\/kg totally) and single doses of anti-D immunoglobulin at 50 ug\/kg, 75 ug\/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience","volume":"24","author":"Alioglu","year":"2013","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/283\/1250383\/bep00113000283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/283\/1250383\/bep00113000283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:24:05Z","timestamp":1594945445000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/283\/20845\/Is-antiD-immunoglobulin-still-a-frontline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.283","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}